TY - JOUR
T1 - Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma
T2 - 3-year study results
AU - Advani, Ranjana H.
AU - Moskowitz, Alison J.
AU - Bartlett, Nancy L.
AU - Vose, Julie M.
AU - Ramchandren, Radhakrishnan
AU - Feldman, Tatyana A.
AU - LaCasce, Ann S.
AU - Christian, Beth A.
AU - Ansell, Stephen M.
AU - Moskowitz, Craig H.
AU - Brown, Lisa
AU - Zhang, Chiyu
AU - Taft, David
AU - Ansari, Sahar
AU - Sacchi, Mariana
AU - Ho, Linda
AU - Herrera, Alex F.
N1 - Publisher Copyright:
© 2021 American Society of Hematology
PY - 2021/8/12
Y1 - 2021/8/12
N2 - This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In parts 1 and 2, patients received staggered dosing of BV and Nivo in cycle 1, followed by same-day dosing in cycles 2 to 4. In part 3, both study drugs were dosed, same day, for all 4 cycles. At end of study treatment, patients could undergo autologous stem cell transplantation (ASCT) per investigator discretion. The objective response rate (ORR; N = 91) was 85%, with 67% achieving a complete response (CR). At a median follow-up of 34.3 months, the estimated progression-free survival (PFS) rate at 3 years was 77% (95% confidence interval [CI], 65% to 86%) and 91% (95% CI, 79% to 96%) for patients undergoing ASCT directly after study treatment. Overall survival at 3 years was 93% (95% CI, 85% to 97%). The most common adverse events (AEs) prior to ASCT were nausea (52%) and infusion-related reactions (43%), all grade 1 or 2. A total of 16 patients (18%) had immune-related AEs that required systemic corticosteroid treatment. Peripheral blood immune signatures were consistent with an activated T-cell response. Median gene expression of CD30 in tumors was higher in patients who responded compared with those who did not. Longer-term follow-up of BV and Nivo as a first salvage regimen shows durable efficacy and impressive PFS, especially in patients who proceeded directly to transplant, without additional toxicity concerns. This trial was registered at www.clinicaltrials.gov as #NCT02572167.
AB - This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In parts 1 and 2, patients received staggered dosing of BV and Nivo in cycle 1, followed by same-day dosing in cycles 2 to 4. In part 3, both study drugs were dosed, same day, for all 4 cycles. At end of study treatment, patients could undergo autologous stem cell transplantation (ASCT) per investigator discretion. The objective response rate (ORR; N = 91) was 85%, with 67% achieving a complete response (CR). At a median follow-up of 34.3 months, the estimated progression-free survival (PFS) rate at 3 years was 77% (95% confidence interval [CI], 65% to 86%) and 91% (95% CI, 79% to 96%) for patients undergoing ASCT directly after study treatment. Overall survival at 3 years was 93% (95% CI, 85% to 97%). The most common adverse events (AEs) prior to ASCT were nausea (52%) and infusion-related reactions (43%), all grade 1 or 2. A total of 16 patients (18%) had immune-related AEs that required systemic corticosteroid treatment. Peripheral blood immune signatures were consistent with an activated T-cell response. Median gene expression of CD30 in tumors was higher in patients who responded compared with those who did not. Longer-term follow-up of BV and Nivo as a first salvage regimen shows durable efficacy and impressive PFS, especially in patients who proceeded directly to transplant, without additional toxicity concerns. This trial was registered at www.clinicaltrials.gov as #NCT02572167.
UR - http://www.scopus.com/inward/record.url?scp=85111237823&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111237823&partnerID=8YFLogxK
U2 - 10.1182/blood.2020009178
DO - 10.1182/blood.2020009178
M3 - Article
C2 - 33827139
AN - SCOPUS:85111237823
SN - 0006-4971
VL - 138
SP - 427
EP - 438
JO - Blood
JF - Blood
IS - 6
ER -